Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3537-3544

  Briolant, Sébastien ^a   Henry, Maud ^a   Oeuvray, Claude ^b   Amalvict, Rémy ^a   Baret, Eric ^a   Didillon, Eric ^c   Rogier, Christophe ^a   Pradines, Bruno ^a  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b Medicines for Malaria Venture   (Switzerland)

^c Fulcrum Pharma (Europe) Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; DOXYCYCLINE; MEFLOQUINE; PIPERAQUINE; PYRIMETHAMINE; QUININE;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; GENETIC ASSOCIATION; GENOME; IC 50; IN VITRO STUDY; NONHUMAN; PFCRT GENE; PFMDR1 GENE; PFMRP GENE; PFNHE GENE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

EID: 77956155765     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00183-10     Document Type: Article

References (55)

1. Arinaitwe, E., T. G. Sandison, H. Wanzira, A. Kahuru, J. Homsy, J. Kalamya, M. R. Kamya, N. Vora, B. Greenhouse, P. J. Rosenthal, J. Tappero, and G. Dorsey. 2009. Artemether-lumefantrine versus dihydroartemisinin- piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin. Infect. Dis. 49:1629-1637.
2. Ashley, E. A., K. M. Lwin, R. Mcgready, W. H. Simon, L. Phaiphun, S. Proux, N. Wangseang, W. Taylor, K. Stepniewska, W. Nawamaneerat, K. L. Thwai, M. Barends, W. Leowattana, P. Olliaro, P. Singhasivanon, N. J. White, and F. Nosten. 2006. An open label randomized comparison of mefloquine-artesunate as separate tablets versus a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Trop. Med. Int. Health 11:1653-1660.
3. Barends, M., A. Jaidee, N. Khaohirun, P. Singhasivanon, and F. Nosten. 2007. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar. J. 6:81.
4. Basco, L. K., and P. Ringwald. 2003. In vitro activity of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob. Agents Chemother. 47:1391-1394.
5. Bassat, Q., M. Mulenga, H. Tinto, P. Piola, S. Borrmann, C. Menendez, M. Nambozi, I. Valea, C. Nabasumba, P. Sasi, A. Bacchieri, M. Corsi, D. Ubben, A. Talisuna, and U. D'Alessandro. 2009. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomized, non-inferiority trial. PLoS One 4:7871.
6. Bogreau, H., F. Renaud, H. Bouchiba, P. Durand, S. B. Assi, M. C. Henry, E. Garnotel, B. Pradines, T. Fusai, B. Wade, E. Adehossi, P. Parola, M. A. Kamil, O. Puijalon, and C. Rogier. 2006. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am. J. Trop. Med. Hyg. 74:953-959.
7. Brasseur, P., P. Agnamey, O. Gaye, M. Vaillant, W. R. J. Taylor, and P. L. Olliaro. 2007. Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Senegal. Malar. J. 6:150.
8. Briolant, S., M. Baragatti, P. Parola, F. Simon, A. Tall, C. Sokhna, P. Hovette, M. Mabika Mamfoumbi, J. L. Koeck, J. Delmont, A. Spiegel, J. P. Gardair, J. F. Trape, M. Kombila, P. Minodier, T. Fusai, C. Rogier, and B. Pradines. 2009. A multi-normal distribution model suitable for the distribution of Plasmodium falciparum in vitro chemosusceptibility to doxycycline. Antimicrob. Agents Chemother. 53:688-695.
9. Briolant, S., N. Wurtz, A. Zettor, C. Rogier, and B. Pradines. 2009. Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. J. Infect. Dis. 201:153-159.
10. Carrara, V. I., J. Zwang, E. A. Ashley, R. N. Price, K. Stepniewska, M. Barends, A. Brockman, T. Anderson, R. McGready, L. Phaiphun, S. Proux, M. van Vugt, R. Hutagalung, K. M. Lwin, A. P. Phyo, P. Preechapornkul, M. Imwong, S. Pukrittayakamee, P. Singhasivanon, N. J. White, and F. Nosten. 2009. Changes in the treatment responses to artesunate-mefloquine on the Northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4:e4451.
11. Crowe, A., K. F. Illett, H. A. Karunajeewa, K. T. Batty, and T. M. E. Davis. 2006. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob. Agents Chemother. 50:3504-3506.
12. Dahl, E. L., and P. J. Rosenthal. 2007. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother. 51:3485-3490.
13. Dahl, E. L., J. L. Shock, B. R. Shenai, J. Gut, J. L. DeRisi, and P. J. Rosenthal. 2006. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob. Agents Chemother. 50: 3124-3131.
14. Davis, T. M. E., J. Hamzah, K. F. Illett, H. A. Karunajeewa, J. C. Reeder, K. T. Batty, S. Hackett, and P. H. R. Barrett. 2006. In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs. Antimicrob. Agents Chemother. 50:2883-2885.
15. Davis, T. M., T. Y. Hung, I. K. Sim, H. A. Karunajeewa, and K. F. Ilett. 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65:75-87.
16. Dondorp, A. M., F. Nosten, P. Yi, D. Das, A. P. Phyo, J. Tarning, K. M. Lwin, F. Ariey, W. Hanpithakpong, S. J. Lee, P. Ringwald, K. Silamut, M. Imwrong, K. Chotivanish, P. Lim, T. Herdman, S. S. An, S. Yeung, P. Singhasivanon, N. P. J. Day, N. Lindegardh, D. Socheat, and N. J. White. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
17. Durrand, V., A. Berry, R. Sem, P. Glaziou, J. Beaudou, and T. Fandeur. 2004. Variations in the sequence and expression of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and their relationship to chloroquine resistance in vitro. Mol. Biochem. Parasitol. 136:273-285.
18. Eastman, R. T., and D. A. Fidock. 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7:864-874.
19. Ezzet, F., R. Mull, and J. Karbwang. 1998. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46:553-561.
20. Ferdig, M. T., R. A. Cooper, J. Mu, B. Deng, D. A. Joy, X. Z. Su, and T. E. Wellems. 2004. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52:985-997.
21. Fivelman, Q. L., I. S. Adagu, and D. C. Warhurst. 2007. Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains. Antimicrob. Agents Chemother. 51:2265-2267.
22. Grande, T., A. Bernasconi, A. Erhart, D. Gamboa, M. Casapia, C. Delgado, K. Torres, C. Fanello, A. Llanos-Cuentas, and U. D'Alessandro. 2007. A randomized controlled trial to assess the efficacy of dihydroartemisininpiperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One 10:e1101.
23. Hasugian, A. R., H. L. E. Purba, E. Kenangalem, R. M. Wuwung, E. P. Ebsworth, R. Maristela, P. M. P. Penttinen, F. Laihad, N. M. Anstey, E. Tjitra, and R. N. Price. 2008. Dihydroartemisinin-piperaquine versus artesunate- amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dis. 44:1067-1074.
24. Henry, M., S. Briolant, A. Fontaine, J. Mosnier, E. Baret, R. Amalvict, T. Fusai, L. Fraisse, C. Rogier, and B. Pradines. 2008. In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 52:2755-2759.
25. + exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob. Agents Chemother. 53:1926-1930.
26. Henry, M., I. Diallo, J. Bordes, S. Ka, B. Pradines, B. Diatta, P. S. M'Baye, M. Sane, M. Thiam, P. M. Gueye, B. Wade, J. E. Touze, J. M. Debonne, C. Rogier, and T. Fusai. 2006. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am. J. Trop. Med. Hyg. 75:146-151.
27. Kamya, M. R., A. Yeka, H. Burkirwa, M. Lugemwa, J. B. Rwakimari, S. G. Staedke, A. O. Talisuna, B. Greenhouse, F. Nosten, P. J. Rosenthal, F. Wabwire-Mangen, and G. Dorsey. 2007. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin. Trials 2:e20.
28. Karunajeewa, H. A., K. F. Ilett, I. Mueller, P. Siba, I. Law, M. Page-Sharp, E. Lin, J. Lammey, K. T. Batty, and T. M. E. Davis. 2008. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52:237-243.
29. Karunajeewa, H. A., I. Mueller, M. Senn, E. Lin, I. Law, P. S. Gomorrai, O. Oa, S. Griffin, K. Kotab, P. Suano, N. Tarongka, A. Ura, D. Lautu, M. Page-Sharp, R. Wong, S. Salman, P. Siba, K. F. Ilett, and T. M. Davis. 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
30. Lakshmanan, V., P. G. Bray, D. Verdier-Pinard, D. J. Johnson, P. Horrocks, R. A. Muhle, G. E. Alakpa, R. H. Hughes, S. A. Ward, D. J. Krogstad, A. B. S. Sidhu, and D. A. Fidock. 2005. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24: 2294-2305.
31. Lambros, C., and J. P. Vanderberg. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420.
32. Le Bras, J., L. Musset, and J. Clain. 2006. Antimalarial drug resistance. Med. Mal. Infect. 36:401-405.
33. Martin, R. E., R. V. Marchetti, A. I. Cowan, S. M. Howitt, S. Bröer, and K. Kirk. 2009. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 325:1680-1682.
34. Muangnoicharoen, S., D. J. Johnson, S. Looareesuwan, S. Krudsood, and S. A. Ward. 2009. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob. Agents Chemother. 53:1362-1366.
35. Mwai, L., S. M. Kiara, A. Abdirahman, L. Pole, A. Rippert, A. Diriye, P. Bull, K. Marsh, S. Borrmann, and A. Nzila. 2009. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob. Agents Chemother. 53:5069-5073.
36. Myint, H. Y., E. A. Ashley, N. P. J. Day, F. Nosten, and N. J. White. 2007. Efficacy and safety of dihydroartemisinin-piperaquine. Trans. R. Soc. Trop. Med. Hyg. 101:858-866.
37. Naudé, B., J. A. Brzostowski, A. R. Kimmel, and T. E. Wellems. 2005. Dictyostelium discoideum expresses a malaria chloroquine resistance mechanism upon transfection with mutant, but not wild-type, Plasmodium falciparum transporter PfCRT. J. Biol. Chem. 280:25596-25603.
38. Nawaz, F., S. L. Nsobya, M. Kiggundu, M. Joloba, and P. J. Rosenthal. 2009. Selection of parasites with diminished drug susceptibility by amodiaquinecontaining antimalarial regimens in Uganda. J. Infect. Dis. 200:1650-1657.
39. Noedl, H., Y. Se, K. Schaecher, B. L. Smith, D. Socheat, and M. M. Fukuda. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
40. Nosten, F., and N. J. White. 2007. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77(Suppl. 6):181-192.
41. Parquet, V., S. Briolant, M. Torrentino-Madamet, M. Henry, L. Almeras, R. Amalvict, E. Baret, T. Fusaï, C. Rogier, and B. Pradines. 2009. Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 53:2248-2252.
42. Premji, Z., R. E. Umeh, S. Owusu-Agyei, F. Esamai, E. U. Ezedinachi, S. Oguche, S. Borrmann, A. Sowunmi, S. Duparc, P. L. Kirby, A. Pamba, L. Kellam, R. Guiguemdé, B. Greenwood, S. A. Ward, and P. A. Winstanley. 2009. Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One 4:e6682.
43. Price, R. N., A. R. Hasugian, A. Ratcliff, H. Siswantoro, H. L. E. Purba, E. Kenangalem, N. Lindegardh, P. Penttinen, F. Laihad, E. P. Ebsworth, N. M. Anstey, and E. Tjitra. 2007. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob. Agents Chemother. 51:4090-4097.
44. Ramharter, M., F. Kurth, A. C. Schreier, J. Nemeth, I. Glasenapp, S. Bélard, M. Schlie, J. Kammer, P. K. Koumba, B. Cisse, B. Mordmüller, B. Lell, S. Issifou, C. Oeuvray, L. Fleckenstein, and P. G. Kremsner. 2008. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis. 198:911-919.
45. Rogers, W. O., R. Sem, T. Tero, P. Chim, P. Lim, S. Muth, D. Socheat, F. Ariey, and C. Wongsrichanalai. 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J. 8:10.
46. Snyder, C., J. Chollet, J. Santo-Tomas, C. Scheurer, and S. Wittlin. 2007. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp. Parasitol. 115:296-300.
47. Tarning, J., E. A. Ashley, N. Lindegardh, K. Stepniewska, L. Phaiphun, N. P. J. Day, R. Mcgready, M. Ashton, F. Nosten, and. N. J. White. 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52:1052-1061.
48. Tarning, J., N. Lindegardh, A. Annerberg, T. Singtoroj, N. P. J. Day, M. Ashton, and N. J. White. 2005. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother. 49:5127-5128.
49. Thanh, N. X., T. N. Truong, N. C. Phong, N. X. Thien, B. Dai, G. D. Shanks, M. Chavchich, and M. D. Edstein. 2009. Open-label randomised comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop. Med. Int. Health 14:504-511.
50. Von Seidlein, L., P. Milligan, M. Pinder, K. Bojang, C. Anyalebechi, R. Gosling, R. Coleman, J. I. Ude, A. Sadiq, M. Duraisingh, D. Warhurst, A. Alloueche, G. Target, K. Mcadam, B. Greenwood, G. Walraven, P. Olliaro, and T. Doherty. 2000. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in The Gambian children: a double-blind, randomized, controlled trial. Lancet 355:352-357.
51. Warhurst, D. C., J. C. Craig, I. S. Adagu, R. K. Guy, P. B. Madrid, and Q. L. Fivelman. 2007. Activity of piperaquine and other 4-aminoquinoline anti-plasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum. Role of β-haematin inhibition and drug concentration in vacuolar water- and lipid-phases. Biochem. Pharmacol. 73:1910-1926.
52. White, N. J. 2001. Preventing antimalarial drug resistance through combinations. Drug Resist. Updat. 1:3-9.
53. Yeka, A., G. Dorsey, M. R. Kamya, A. Talisuna, M. Lugemwa, J. B. Rwakimari, S. G. Staedke, P. J. Rosenthal, F. Wabwire-Mangen, and H. Bukirwa. 2008. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 3:e2390.
54. Zongo, I., G. Dorsey, N. Rouamba, C. Dokomajilar, Y. Séré, P. J. Rosenthal, and J. B. Ouédraogo. 2007. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin- piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina-Faso. Clin. Infect. Dis. 45:1453-1461.
55. Zwang, J., E. A. Ashley, C. Karema, U. D'Alessandro, F. Smithuis, G. Dorsey, B. Janssens, M. Mayxay, P. Singhasivanon, K. Stepniewska, N. J. White, and F. Nosten. 2009. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4:6358.